IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	MEN1703 Sensitive: C2 – Inclusion Criteria MEN1703 Sensitive : C2	MEN1703 Sensitive: C2 – Inclusion Criteria MEN1703 Sensitive : C2
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	MEN1703 Sensitive: C3 – Early Trials MEN1703 Sensitive : C3	MEN1703 Sensitive: C3 – Early Trials MEN1703 Sensitive : C3
PIM1 mutation	Diffuse Large B Cell Lymphoma	PIM1 mutation	Diffuse Large B Cell Lymphoma	venetoclax + ibrutinib + AZD1208 Sensitive: D – Preclinical venetoclax + ibrutinib + AZD1208 Sensitive : D	venetoclax + ibrutinib + AZD1208 Sensitive: D – Preclinical venetoclax + ibrutinib + AZD1208 Sensitive : D
PAI1 expression	Rectal Cancer	PAI1 expression	Rectal Cancer	AZD1208 Sensitive: D – Preclinical AZD1208 Sensitive : D	AZD1208 Sensitive: D – Preclinical AZD1208 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib + AZD1208 Sensitive: D – Preclinical quizartinib + AZD1208 Sensitive : D	quizartinib + AZD1208 Sensitive: D – Preclinical quizartinib + AZD1208 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	gilteritinib + AZD1208 Sensitive: D – Preclinical gilteritinib + AZD1208 Sensitive : D	gilteritinib + AZD1208 Sensitive: D – Preclinical gilteritinib + AZD1208 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	EC-70124 Sensitive: D – Preclinical EC-70124 Sensitive : D	EC-70124 Sensitive: D – Preclinical EC-70124 Sensitive : D

PIM inhibitor

PIM inhibitor

Associations(7)

Associations
(7)